Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SEHK: 2315)
Health Care · Biotechnology · CN
HK$69.00
+11.65% today · +184.9% 1Y
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SEHK: 2315) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.37B and employs 1,443 people.
Over the last twelve months the share price has gained 184.9%, trading between 20.30 and 75.30.
Tweenvest scores Biocytogen Pharmaceuticals (Beijing) Co., Ltd. across four factors: quality 67/100, value 18/100, growth 100/100. Its strongest factor is growth.
2315 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.37B
- Revenue (TTM)
- $226.54M
- P/E
- 84.74
- EPS
- 0.72
- Dividend yield
- —
- Beta (5Y)
- 0.14
- 52-week high
- HK$75.30
- 52-week low
- HK$20.30
- Avg volume (3M)
- —
- Shares outstanding
- 446.90M
- Employees
- 1,443
- Next earnings
- —
About Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
- ISIN
- CNE100005D27
- Founded
- 2008
- Listed since
- Sep 1, 2022
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.